| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
156,320,000 |
| Market
Cap: |
6.26(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$20.26 - $43.27 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cerevel Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co.'s programs: Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype; Darigabat, which is a PAM that selectively targets the alpha-2/3/5 subunits of the GABAA receptor; Tavapadon, which is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of early- and late-stage Parkinson's disease; and CVL-871, which is a selective dopamine D1/D5 receptor partial agonist specifically designed to achieve a level of partial agonism.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
17,422,701 |
18,847,701 |
| Total Buy Value |
$0 |
$0 |
$397,510,553 |
$447,385,553 |
| Total People Bought |
0 |
0 |
6 |
6 |
| Total Buy Transactions |
0 |
0 |
6 |
7 |
| Total Shares Sold |
150,000 |
381,632 |
659,132 |
1,300,893 |
| Total Sell Value |
$6,252,285 |
$15,864,974 |
$23,446,852 |
$43,726,088 |
| Total People Sold |
1 |
8 |
8 |
10 |
| Total Sell Transactions |
3 |
17 |
27 |
50 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Renger John |
Chief Scientific Officer |
• – – |
2021-12-21 |
4 |
AS |
$32.50 |
$237,250 |
D/D |
(7,300) |
1,980 |
|
-8% |
|
| Renger John |
Chief Scientific Officer |
• – – |
2021-12-21 |
4 |
OE |
$3.50 |
$25,550 |
D/D |
7,300 |
9,280 |
|
- |
|
| Renger John |
Chief Scientific Officer |
• – – |
2021-12-17 |
4 |
AS |
$32.50 |
$231,465 |
D/D |
(7,122) |
1,980 |
|
-7% |
|
| Renger John |
Chief Scientific Officer |
• – – |
2021-12-17 |
4 |
OE |
$3.50 |
$24,927 |
D/D |
7,122 |
9,102 |
|
- |
|
| Renger John |
Chief Scientific Officer |
• – – |
2021-12-16 |
4 |
AS |
$32.50 |
$181,285 |
D/D |
(5,578) |
1,980 |
|
4% |
|
| Renger John |
Chief Scientific Officer |
• – – |
2021-12-16 |
4 |
OE |
$3.50 |
$19,523 |
D/D |
5,578 |
7,558 |
|
- |
|
| Renger John |
Chief Scientific Officer |
• – – |
2021-12-15 |
4 |
AS |
$30.02 |
$750,448 |
D/D |
(25,000) |
1,980 |
|
-1% |
|
| Renger John |
Chief Scientific Officer |
• – – |
2021-12-15 |
4 |
OE |
$3.50 |
$87,500 |
D/D |
25,000 |
26,980 |
|
- |
|
| Renger John |
Chief Scientific Officer |
• – – |
2021-11-10 |
4 |
AS |
$38.59 |
$2,192,187 |
D/D |
(55,000) |
0 |
|
-12% |
|
| Renger John |
Chief Scientific Officer |
• – – |
2021-11-10 |
4 |
OE |
$3.50 |
$192,500 |
D/D |
55,000 |
55,000 |
|
- |
|
| Dekkers Marijn E |
Director |
– • – |
2021-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,270 |
42,810 |
|
- |
|
| Pf Equity Holdings 1 B.v. |
10% Owner |
– – • |
2021-09-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
27,349,211 |
|
-31% |
|
| Edelman Joseph |
Director |
– • – |
2021-08-26 |
4 |
B |
$30.23 |
$2,057,061 |
I/I |
68,047 |
5,086,727 |
2.1 |
4% |
|
| Edelman Joseph |
Director |
– • – |
2021-08-25 |
4 |
B |
$28.57 |
$1,753,827 |
I/I |
61,387 |
5,018,680 |
2.1 |
11% |
|
| Edelman Joseph |
Director |
– • – |
2021-08-24 |
4 |
B |
$27.73 |
$1,934,473 |
I/I |
69,761 |
4,957,293 |
2.1 |
17% |
|
| Edelman Joseph |
Director |
– • – |
2021-08-23 |
4 |
B |
$25.78 |
$1,145,586 |
I/I |
44,437 |
4,887,532 |
2.1 |
30% |
|
| Edelman Joseph |
Director |
– • – |
2021-07-07 |
4 |
B |
$25.00 |
$5,000,000 |
I/I |
200,000 |
4,843,095 |
2.1 |
66% |
|
| Greene Gabrielle E |
Director |
– • – |
2021-06-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,270 |
49,624 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2021-06-17 |
4 |
B |
$13.06 |
$275,357 |
D/D |
21,084 |
35,354 |
2.39 |
195% |
|
| Mishan Orly |
Chief Business Officer |
• – – |
2021-01-26 |
4 |
OE |
$3.50 |
$134,575 |
D/D |
38,450 |
38,450 |
|
- |
|
| Riedel Norbert G |
Director |
– • – |
2021-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,270 |
28,540 |
|
- |
|
| Koppel Adam |
Director |
– • • |
2020-11-09 |
4 |
B |
$10.30 |
$3,422,618 |
I/I |
332,293 |
60,632,356 |
2.25 |
75% |
|
| Bain Capital Partners Xii, Llc |
10% Owner |
– – • |
2020-11-09 |
4 |
B |
$10.30 |
$3,422,618 |
I/I |
332,293 |
60,632,356 |
1.5 |
75% |
|
| Gordon Christopher R |
Director |
– • • |
2020-11-09 |
4 |
B |
$10.30 |
$3,422,618 |
I/I |
332,293 |
60,632,356 |
2.25 |
75% |
|
| Dipietro Kenneth |
Chief Human Resources OfficerO |
• – – |
2020-10-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,270 |
|
36% |
|
194 Records found
|
|
Page 7 of 8 |
|
|
0.24 (0.6%) 
